沙美特罗／氟替卡松与噻托溴铵治疗慢性阻塞性肺疾病的临床效果

目的：探讨沙美特罗/氟替卡松噻托溴铵治疗COPD的临床疗效。方法选择78例COPD患者，按照入院先后随机分为两组，对照组39例在基础治疗同时给予沙美特罗/氟替卡松，观察组39例在对照组治疗基础上加用噻托溴铵，比较两组FVC、FEV1和FEV1/FVC及不良反应发生率。结果观察组治疗后FVC、FEV1和FEV1/FVC分别为（1．90±0．19） L、（2．26±0．25） L和（68．41±5．65）％，均显著高于治疗前（t（观察组）＝9．92，11．62，9．72；t（对照组）＝9．70、8．76、9．41，均P＜0．05）和对照组治疗后（t＝8．37、7．72、7．52，均P＜0．05）；两组不良反应发生率差异无统计学意义（χ2＝2．207，P＞0．05）。结论沙美特罗/氟替卡松联合噻托溴铵治疗COPD效果显著，且安全可靠。

The clinical effect of salmeterol and fluticasone propionate combined with tiotropium in the treatment of chronic obstructive pulmonary disease

Objective To investigate the clinical effects of salmeterol and fluticasone propionate combined with tiotropium in treatment of chronic obstructive pulmonary disease （COPD）.Methods 78 patients with COPD were randomly divided into two groups according to hospitalized order ,the control group（n=39）was given salmeterol and fluticasone propionate on the basis of the conventional treatment while the observation group （ n=39 ） was given tiotropium on the basis of the control group .The clinical efficacy and adverse events were compared between the two groups.Results After treatment,FVC,FEV1 and FEV1/FVC of the observation group were （1.90 ±0.19） L, （2.26 ±0.25）L and（68.41 ±5.65）%,which were significantly higher than those before treatment （t2 =9.92, 11.62,9.72;t1=9.70,8.76,9.41,all P〈0.05）and of the control group（t=8.37,7.72,7.52,all P〈0.05）;the incidenceof adverse reactions had no statistically significant between the two groups （χ2 =2.207, P 〉0.05 ）. Conclusion Salmeterol and fluticasone propionate combination of tiotropium in the treatment of COPD has significant effect,and it can effectively alleviate clinical symptoms and improve lung function ,so it is safe and reliable,which should be widely applied in clinical .